FDMT
4D Molecular·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 3
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About FDMT
4d Molecular Therapeutics, Inc.
A clinical-stage biotherapeutics company that develops therapies for genetic diseases
Biological Technology
03/11/2015
12/11/2020
NASDAQ Stock Exchange
227
12-31
Common stock
5858 Horton Street #455, Emeryville, CA 94608
--
4D Molecular Therapeutics, Inc., was incorporated under the laws of the State of Delaware on March 11, 2015. The Company is a leading clinical-stage biopharmaceutical company focused on unlocking the full potential of genetic medicines through proprietary custom vectors optimized for disease-specific treatments.
Company Financials
EPS
FDMT has released its 2025 Q3 earnings. EPS was reported at -1.01, versus the expected -0.98, missing expectations. The chart below visualizes how FDMT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
FDMT has released its 2025 Q3 earnings report, with revenue of 90.00K, reflecting a YoY change of 2900.00%, and net profit of -56.88M, showing a YoY change of -29.73%. The Sankey diagram below clearly presents FDMT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
